Evidence map›Paper›PMID 37563531›Full record

ArticleBulletin of experimental biology and medicine2023

Benzimidazole-Carboxamides as Potential Therapeutics for Alzheimer's Disease: Primary Analysis In Silico and In Vitro.

Yu V Chelusnova, P A Voronina, D A Belinskaia, N V Goncharov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Serotonergic Regulation in Alzheimer's Disease.International journal of molecular sciences · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yu V ChelusnovaResearch Institute of Hygiene, Occupational Pathology and Human Ecology, Federal Medical-Biological Agency of Russia, Leningrad Region, Kuzmopavlovsky, Russia.
P A VoroninaI. M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia.
D A BelinskaiaI. M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia.
N V GoncharovI. M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia. ngoncharov@gmail.com.
Institute of Evolutionary Physiology and Biochemistry · RUFederal Medical-Biological Agency · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A primary in vitro analysis of the anticholinesterase properties of substituted 1,3-dihydro-2-oxo-1H-benzimidazol-2-ones was performed along with in silico calculation of their oral toxicity. These compounds are analogs of BIMU-8, a well-known agonist of serotonin 5-HT

Indexed as

Alzheimer DiseaseButyrylcholinesteraseAcetylcholinesteraseBenzimidazolesCholinesterase InhibitorsHumansMolecular Docking SimulationReceptors, SerotoninStructure-Activity RelationshipAcetylcholinesteraseBenzimidazolesButyrylcholinesteraseCholinesterase InhibitorsReceptors, SerotoninAlzheimer’s diseasebenzimidazolonescholinesterasesreceptors

Identifiers

PMID37563531
OpenAlexW4385719342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.